TNFSF11 and metabolic dysfunction-associated steatotic liver disease: Moreover, Mantovani et al., trying to access bone turnover markers in postmenopausal T2DM patients with and without NAFLD (10 patients with NAFLD and fibrosis, 52 with NAFLD and without fibrosis, and 15 without NAFLD), found that RANKL levels gradually diminished from the study patients without NAFLD, to those with steatosis and then to those with steatosis and fibrosis, while sclerostin levels were higher in patients with NAFLD (46).